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Summary
One of the most exciting areas of current research in the cannabinoid field is the study of the potential application of these
compounds as antitumoral drugs. Here, we describe the signaling pathway thatmediates cannabinoid-induced apoptosis of
tumor cells. By using a wide array of experimental approaches, we identify the stress-regulated protein p8 (also designated
as candidate of metastasis 1) as an essential mediator of cannabinoid antitumoral action and show that p8 upregulation is
dependent on de novo-synthesized ceramide. We also observe that p8 mediates its apoptotic effect via upregulation of the
endoplasmic reticulum stress-related genes ATF-4, CHOP, and TRB3. Activation of this pathway may constitute a potential
therapeutic strategy for inhibiting tumor growth.Introduction
The hemp plant Cannabis sativa produces approximately 60
unique compounds known as cannabinoids, of which D9-tetra-
hydrocannabinol (THC) is the most important, owing to its high
potency and abundance in cannabis (Gaoni and Mechoulam,
1964). THC exerts a wide variety of biological effects by mimick-
ing endogenous substances—the endocannabinoids ananda-
mide (Devane et al., 1992) and 2-arachidonoylglycerol (Mechou-
lam et al., 1995)—that bind to and activate specific cannabinoid
receptors. So far, two cannabinoid-specific Gi/o protein-coupled
receptors have been cloned and characterized from mammalian
tissues (Howlett et al., 2002): CB1 (Matsuda et al., 1990), partic-
ularly abundant in the brain, and CB2 (Munro et al., 1993), mainly
expressed in the immune system.
One of the most exciting areas of current research in the can-
nabinoid field is the study of the potential application of canna-
binoids as therapeutic agents (Di Marzo et al., 2004; Piomelli,
2003). Among these possible applications, cannabinoids are be-
ing investigated as potential antitumoral drugs (Guzman, 2003).CANCER CELL 9, 301–312, APRIL 2006 ª2006 ELSEVIER INC. DOI 10.10Thus, cannabinoid administration has been shown to curb the
growth of several models of tumor xenografts in rats and mice
(Guzman, 2003). This antitumoral action of cannabinoids relies,
at least in part, on their ability to induce apoptosis of tumor cells
(Casanova et al., 2003; Galve-Roperh et al., 2000; McKallip
et al., 2002; Ruiz et al., 1999; Sanchez et al., 1998; Sarfaraz
et al., 2005). In addition, cannabinoids have been shown to in-
hibit tumor angiogenesis (Blazquez et al., 2003, 2004; Portella
et al., 2003). Studies conducted in glioma (Blazquez et al.,
2004; Galve-Roperh et al., 2000; Gomez del Pulgar et al.,
2002a) and prostate tumor (Mimeault et al., 2003) cells support
that the antitumoral effect of cannabinoids is associated with an
accumulation of the proapoptotic sphingolipid ceramide (Ogret-
men and Hannun, 2004). However, the downstream targets of
this metabolite and the participation of additional signaling path-
ways in the proapoptotic effect of cannabinoids remain to be
elucidated. Here, we used tumor cells with different sensitiv-
ity to cannabinoid-induced apoptosis to investigate the molec-
ular mechanisms involved in the antitumoral action of these
compounds.S I G N I F I C A N C E
Marijuana has been used inmedicine formanycenturies, and nowadays there is a renaissance in the study of the therapeutic effects of
cannabinoids. One of themost active areas of research in the cannabinoid field is the study of the potential antitumoral application of
these drugs. Our results unravel themechanism of cannabinoid antitumoral action by demonstrating the proapoptotic role of the stress
protein p8 via its downstream targets ATF-4, CHOP, and TRB3. The identification of this pathway may contribute to the design of thera-
peutic strategies for inhibiting tumor growth. In particular, our findings can help to improve the efficiency and selectivity of potential
antitumoral therapies with cannabinoids.16/j.ccr.2006.03.005 301
A R T I C L EResults
THC-induced apoptosis involves upregulation of several
stress-regulated genes
We used two subclones of C6 glioma cells designated as C6.9
and C6.4 as a first step to investigate the proapoptotic action
of THC. C6.4 cells exhibit a lower sensitivity to cannabinoid-
induced apoptosis than C6.9 cells (Figure 1A and Galve-Roperh
et al., 2000). By using DNA arrays, we analyzed the gene expres-
sion profile of C6.9 and C6.4 cells in response to THC (1.6 mM) at
a time point (18 hr) at which no changes in viability were evident
yet (Figure 1B, inset). The entire list of genes that were differen-
tially expressed in THC-treated C6.9 and C6.4 cells as com-
pared with their corresponding controls can be found as Tables
S1 and S2 in the Supplemental Data available with this article
online. Data analysis showed a series of stress-associated
genes that were selectively upregulated in C6.9 but not C6.4
cells (Figure 1B). One of these genes was that encoding the
stress-regulated protein p8 (also known as candidate of metas-
tasis 1), a protein that belongs to the family of HMG-I/Y tran-
scription factors and that has been previously implicated in
the control of cell fate (Jiang et al., 2005b; Malicet et al., 2003;
Su et al., 2001; Vasseur et al., 2002a). By using real-time quan-
titative PCR, we confirmed that THC upregulates p8 mRNA
levels in C6.9 but not in C6.4 cells (Figure 1C). Likewise, Western
blot analysis showed that THC increases p8 protein levels in
C6.9 but not in C6.4 cells (Figure 1D). As accumulation of de
novo-synthesized ceramide has been implicated in the mecha-
nism of cannabinoid-induced apoptosis of glioma cells (Galve-
Roperh et al., 2000; Gomez del Pulgar et al., 2002a), we tested
whether ceramide accumulation is involved in the regulation of
p8. Preincubation with 1 mM ISP-1—a selective inhibitor of ser-
ine palmitoyltransferase, the enzyme that catalyzes the rate-
limiting step of sphingolipid biosynthesis—prevented THC-
induced p8 upregulation (Figure 1E).
p8 mediates THC-induced apoptosis
We next investigated the involvement of p8 in THC-induced
apoptosis of human tumor cells. THC treatment decreased via-
bility, activated caspase 3, and induced p8 in astrocytoma
U87MG, oligodendroglioma Gos3, pancreatic cancer MiaPaCa2,
and melanoma A375 cells (Figure S1), supporting the idea that
p8 upregulation may be a general event in THC-induced apopto-
sis. We selected U87MG cells for further studies and verified
that THC induces apoptosis of these cells (Figure S2A) and
that mitochondria (Figures S2B and S2C) and caspases (Fig-
ure S2D) are involved in this effect.
Incubation of U87MG cells with ISP-1 (1 mM), the selective
CB1 receptor antagonist SR141716 (1 mM), or the selective
CB2 receptor antagonist SR144528 (1 mM) prevented cell death
(Figure 2A) and ceramide accumulation (Figure 2B). We con-
firmed that ceramide is involved in the regulation of p8 also in
these cells, as pharmacological inhibition of ceramide synthesis
de novo reduced by w50% the THC-triggered increase in p8
levels (Figure 2C). Likewise, incubation of U87MG cells with
the ceramide analog C2-ceramide (3 mM; 18 hr) increased p8
mRNA expression (Figure 2D). Since conversion to complex
sphingolipids has been implicated in the regulation of the pro-
apoptotic role of ceramide (Gouaze et al., 2005; Ogretmen
and Hannun, 2004), we investigated whether cannabinoid treat-
ment affected accumulation of these sphingolipids. Selective302knockdown (Figure 2E) or pharmacological inhibition (Figure 2F)
of glucosylceramide synthase (GCS)—the enzyme that cata-
lyzes the rate-limiting step of glycosphingolipid biosynthesis
(Ogretmen and Hannun, 2004)—did not significantly modify
the effect of THC on cell viability or p8 expression (data not
shown). In addition, THC did not produce major changes in
U87MG glycosphingolipid profile (Figure 2G), suggesting
Figure 1. p8 is upregulated in cannabinoid-sensitive glioma cells
A: Effect of THC on C6.9 and C6.4 cell viability after 72 hr of treatment (n = 6;
**p < 0.01 and *p < 0.05 from vehicle-treated cells).
B: Stress-related genes differentially upregulated in the gene array analysis
of THC-treated C6.9 versus C6.4 cells (n = 3). ASNS, asparagine synthetase.
Inset: effect of THC (1.6 mM) on C6.9 and C6.4 cell viability (n = 6; **p <
0.01 from vehicle-treated cells).
C: Effect of THC on p8 mRNA levels (as determined by real-time quantitative
PCR) in C6.9 and C6.4 cells (n = 3; **p < 0.01 from vehicle-treated C6.9 cells).
D: Effect of THC on p8 protein expression in C6.9 and C6.4 cells (n = 2; a rep-
resentative Western blot experiment is shown).
E: Effect of ISP-1 on THC-induced p8 expression of C6.9 cells (n = 4; **p < 0.01
from vehicle-treated cells; ##p < 0.01 from THC-treated cells).
Data in A–C and E are expressed as mean 6 standard deviation. (Bars cor-
respond to standard deviation.)CANCER CELL APRIL 2006
A R T I C L EFigure 2. De novo-synthesized ceramide mediates THC-induced p8 upregu-
lation and apoptosis
A: Effect of THC on the viability of U87MG cells preincubated with vehicle,
SR141716 (SR1), SR144528 (SR2), or ISP-1 (n = 4; **p < 0.01 from vehicle-treated
cells; ##p < 0.01 and #p < 0.05 from THC-treated cells).
B: Effect of THC on ceramide levels of U87MG cells preincubated with vehi-
cle, SR1, SR2, or ISP-1 (n = 3; **p < 0.01 from vehicle-treated cells; ##p < 0.01
from THC-treated cells).
C: Effect of ISP-1 on THC-induced upregulation of p8 mRNA levels (n = 6;
a representative RT-PCR experiment is shown). Values of gene induction
as determined by real-time quantitative PCR (expressed as mean fold in-
crease 6 SD relative to vehicle-treated cells; n = 6; **p < 0.01 and *p <
0.05 from vehicle-treated cells; ##p < 0.01 from THC-treated cells) are shown
in parentheses.
D: Effect of C2-ceramide on p8 mRNA levels (n = 3; a representative RT-PCR
experiment is shown). Values of gene induction as determined by real-time
quantitative PCR (expressed as fold increase relative to vehicle-treated cells
in that experiment) are shown in parentheses.
E: Effect of THC on the viability of U87MG cells transfected with a control
(siRNAC) or a GCS-selective (siRNA GCS) siRNA (n = 3; **p < 0.01 from vehi-
cle-treated cells). Upper panel: a representative RT-PCR of siRNAC and
siRNA GCS vehicle-treated cells is shown.
F: Effect of THC on the viability of U87MG cells preincubated with vehicle,
1 mM DL-Threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP)
or 200 mM N-(n-butyl)deoxynojirimycin (NDJ) (n = 6; **p < 0.01 from vehicle-
treated cells).
G: Effect of THC on the glycosphingolipid profile of U87MG cells. A represen-
tative experiment of two is shown. Total dpm in the ganglioside fraction:
Veh = 32134, THC = 29129. Total dpm in the neutral glycolipid fraction:CANCER CELL APRIL 2006that conversion of ceramide to complex sphingolipids does not
play a major role in the proapoptotic effect of THC.
To determine the role of p8 in the triggering of THC-induced
apoptosis, we employed siRNA to selectively reduce the ex-
pression of this protein. Knockdown of p8 mRNA levels pre-
vented U87MG cell death induced by both THC (Figure 3A)
and C2-ceramide (3 mM; 24 hr; Figure 3B). In addition, pharma-
cological blockade of the mitochondrial respiratory chain pre-
vented THC-induced cell death (Figure S2B) but not p8 upregu-
lation (Figure 3D), supporting an early premitochondrial role for
p8 in THC-induced apoptosis. To further support the involve-
ment of p8 in the proapoptotic effect of THC, we used p8+/+
and p8-deficient RasV12/E1A-transformed mouse embryonic fi-
broblasts (MEFs) (Vasseur et al., 2002b) (we verified that these
express CB receptors; Figure S3A). THC (7 mM) induced apopto-
sis (72 hr, Figure 3C; 48 hr, Figure S3B) and decreased the mi-
tochondrial membrane potential (18 hr, Figure 3E) of p8+/+ but
not p8-deficient cells.
p8 controls several endoplasmic reticulum
stress-regulated genes to induce apoptosis
To investigate the downstream targets of p8 that participate in
its proapoptotic action, we first analyzed the gene expression
profile of p8-deficient MEFs infected with an empty or a p8-
overexpressing retroviral vector. The entire list of genes that
were differentially expressed in the p8-overexpressing cells
can be found as Table S3. Interestingly, when we compared
the genes selectively modulated in p8-overexpressing MEFs
with those selectively modulated by THC in cannabinoid-sensi-
tive glioma cells, we found several common ones, including
those encoding the activating transcription factor-4 (ATF-4)
and the stress-regulated protein tribbles homolog 3 (TRB3,
also known as cell death-inducible kinase, NIPK, and SKIP3)
(Figure 4A), that are involved in the response to endoplasmic re-
ticulum (ER) stress (Ohoka et al., 2005). We confirmed by real-
time quantitative PCR that THC upregulates ATF-4 and TRB3
in C6.9 but not in C6.4 cells (Figure 4B). In addition, C6.4 cells
forced to overexpress p8 in a stable fashion exhibited increased
levels of ATF-4 and TRB3 mRNA (Figure 4C). Moreover, ATF-4
and TRB3 mRNA levels were lower in p8-deficient MEFs than
in their corresponding p8+/+ counterparts (Figure 4D).
It has been recently shown that ATF-4 cooperates with C/EBP
homologous protein (CHOP, also known as DDIT3) (Ma et al.,
2002) to regulate TRB3 as part of the ER stress apoptotic path-
way (Ohoka et al., 2005). In U87MG cells, THC induced upregu-
lation of ATF-4, CHOP, and TRB3 mRNA levels (Figure 5A), an
effect that was reduced by knockdown of p8 expression
(Figure 5A) or incubation with ISP-1 (Figure 5B). Likewise, incu-
bation of U87MG cells with the ceramide analog C2-ceramide
(3.0 mM; 18 hr) increased ATF-4, CHOP, and TRB3 mRNA
expression (Figure 5C). Moreover, THC treatment induced
ATF-4, CHOP, and TRB3 upregulation in p8+/+ but not in p8-
deficient transformed MEFs (Figure 5D), further confirming the
involvement of p8 in the cannabinoid-induced upregulation of
these genes.
Veh = 129765, THC = 73357. SM, sphingomyelin; Trihex-Cer, trihexosylcera-
mide; Dihex-Cer, dihexosylceramide; Monohex-Cer, monohexosylcera-
mide.
Data in A–C, E, and F are expressed as mean 6 standard deviation. (Bars in
A, B, E, and F correspond to standard deviation.)303
A R T I C L EFigure 3. p8 is required for THC-induced apoptosis
A: Effect of THC on the viability of U87MG cells transfected with a control
(siRNAC) or a p8-selective (siRNAp8) siRNA (n = 6). Upper panel: real-time
quantitative PCR analysis of p8 mRNA levels in siRNAC-and siRNAp8-trans-
fected cells (n = 3; a representative RT-PCR of siRNAC and siRNAp8 vehi-
cle-treated cells is shown). **p < 0.01 and *p < 0.05 from vehicle-treated
cells; ##p < 0.01 from the corresponding siRNAC-transfected cells.
B: Effect of C2-ceramide on the viability of U87MG cells transfected with
siRNAC or siRNAp8 (n = 3; **p < 0.01 from vehicle-treated cells; #p < 0.05
from C2-ceramide-treated siRNAC cells).
C: Effect of THC on the viability of p8+/+ and p8-deficient RasV12/E1A-trans-
formed MEFs (n = 5; **p < 0.01 and *p < 0.05 from vehicle-treated cells;
##p < 0.01 from THC-treated MEF p8+/+ cells). Upper panel: effect of THC
on p8 expression of p8+/+and p8-deficient cells (n = 2; a representative
RT-PCR experiment is shown).304To test whether these ER stress-related proteins were in-
volved in cannabinoid-induced apoptosis, we selectively
knocked down ATF-4 and TRB3 mRNA levels in U87MG cells.
siRNA for either ATF-4 (Figure 5E) or TRB3 (Figure 5F) blunted
THC-induced cell death, indicating that THC triggers a p8-medi-
ated response that involves ATF-4, CHOP, and TRB3 upregula-
tion to induce apoptosis (Figure 5G).
Activation of the ER stress pathway sensitizes tumor
cells to apoptosis
Next, we studied whether enforced expression of p8 or TRB3 af-
fected the viability of the cannabinoid-resistant cell line C6.4. p8
or TRB3 overexpression did not induce apoptosis by itself (data
not shown) but sensitized these cells to a further cannabinoid
treatment (Figures 6A and 6B). p8-overexpressing C6.4 cells
also became sensitized to the ER stress inducers tunicamycin
and thapsigargin (data not shown). In addition, p8-deficient
transformed MEFs were more resistant to tunicamycin and
thapsigargin than their corresponding p8+/+ counterparts (Fig-
ures 6C and 6D), supporting an important role for p8 in the
response to ER stress. We therefore studied the cooperative
action of THC with these agents as well as with cisplatin and
doxorubicin—two frequently used chemotherapeutic drugs.
Submaximal doses of thapsigargin, cisplatin, or doxorubicin
and THC reduced U87MG cell viability in a synergic fashion (Fig-
ures 6E, 6G, and 6H). An additive effect was observed when tu-
nicamycin and THC were administered to these cells (Figure 6F).
We subsequently tested whether the aforementioned canna-
binoid effects were selective of tumor cells. Of interest, THC
challenge of astrocytes, the normal counterparts of astrocytoma
cells, did not affect either viability or expression of p8, ATF-4,
TRB3, and other ER stress-related genes (Figure S4), indicating
that cannabinoid treatment does not activate the proapoptotic
route described above in nontransformed cells.
THC treatment leads to p8 upregulation in vivo
To give further relevance to these findings, we generated tumors
by subcutaneously injecting human U87MG astrocytoma cells in
mice. Administration of THC (15 mg/kg/day, 14 days) signifi-
cantly reduced tumor growth (Figure 7A) and increased apopto-
sis (Figure 7B) in these tumors. This correlated with increased
immunostaining (Figure 7C) and mRNA levels (Figure 7D) of
p8. Activation of this pathway was further confirmed by the up-
regulation of TRB3 (Figure 7D).
In order to confirm the in vivo relevance of p8 in the cannabi-
noid-induced ER stress-dependent proapoptotic action, we
generated tumors by subcutaneously injecting p8+/+ or p8-defi-
cient transformed MEFs. THC (15 mg/kg/day, 8 days) signifi-
cantly reduced tumor growth and induced apoptosis of p8+/+
D: Effect of rotenone on THC-induced upregulation of p8 mRNA levels (n = 3;
a representative RT-PCR experiment is shown). Values of gene induction as
determined by real-time quantitative PCR (expressed as fold increase rela-
tive to vehicle-treated cells in that experiment) are shown in parentheses.
E: Effect of THC on mitochondrial membrane potential of p8+/+ (upper
panels) or p8-deficient (lower panels) RasV12/E1A-transformed MEFs (n = 3;
*p < 0.05 from vehicle-treated cells). A dot plot of a representative experi-
ment is shown in the right panels. Values in the lower left corner of each
plot correspond to the percentage of low TMRM/Hoechst-negative cells
in that experiment.
Data in A–C and E are expressed as mean 6 standard deviation. (Bars cor-
respond to standard deviation.)CANCER CELL APRIL 2006
A R T I C L EFigure 4. p8 controls ATF-4 and TRB3 to induce apoptosis
A: Genes differentially expressed in p8-overexpressing RasV12/E1A-trans-
formed p82/2 MEF and THC-treated C6.9 cells. Results are expressed as
mean fold induction6 SD relative to empty vector-infected MEFs or to vehi-
cle-treated C6.9 cells. ASNS, asparagine synthetase. Right panel: ATF-4 and
TRB3 mRNA levels ofp8-deficient RasV12/E1A-transformed MEFs infected with
an empty or a (human) p8-overexpressing vector (n = 3; a representative RT-
PCR is shown). h p8, probe for human p8.
B: Effect of THC on ATF-4 and TRB3 mRNA levels (as determined by real-time
quantitative PCR) in C6.9 and C6.4 cells (n = 3; **p < 0.01 from vehicle-
treated C6.9 cells).
C: Effect of p8 overexpression on ATF-4 and TRB3 mRNA levels (as deter-
mined by real-time quantitative PCR) of C6.4 cells. A representative exper-
iment is shown. Upper panel: analysis of h p8 mRNA levels in cells infected
with empty and p8-overexpressing retroviral vector (a representative RT-
PCR experiment is shown).
D: ATF-4 and TRB3 mRNA levels of p8+/+ and p8-deficient RasV12/E1A-trans-
formed MEFs (n = 3; a representative RT-PCR is shown).
Data in A and B are expressed as mean 6 standard deviation. (Bars corre-
spond to standard deviation.)CANCER CELL APRIL 2006(Figures 7E and 7F) but not of p8-deficient (Figures 7G and 7H)
tumors.
We next studied the involvement of the p8 pathway in the
antitumoral action of THC in astrocytoma cells obtained from
patient biopsies. Cells obtained from human glioblastoma 1
(HG1) were more sensitive to the cannabinoid than cells ob-
tained from human glioblastoma 2 (HG2) (Figure 8A). Likewise,
upregulation of p8, ATF-4, CHOP, and TRB3 in response to
THC (6 mM; 18 hr) was higher in HG1 than in HG2 cells (Fig-
ure 8B). Finally, we analyzed the tumors of two patients enrolled
in a clinical trial aimed at investigating the effect of THC on recur-
rent glioblastoma multiforme. The patients were subjected to
local THC administration, and biopsies were taken before and
after the treatment. In the two patients, both apoptosis (Fig-
ure 8C) and p8 immunoreactivity (Figure 8D) were increased
after cannabinoid inoculation.
Discussion
Cannabinoids have been shown to exert antiproliferative actions
on a wide spectrum of tumor cells. Data presented here now
shed light on the mechanism responsible for these actions by
elucidating the signaling pathway that mediates cannabinoid-
induced apoptosis. In particular, different observations strongly
support a major role for the stress-regulated protein p8 in the
triggering of THC proapoptotic action: (1) THC leads to p8 upre-
gulation and apoptosis in several tumor cells as well as in cells
obtained from human astrocytoma biopsies; (2) p8 upregulation
does not occur in cannabinoid-resistant tumor cells; (3) p8-
deficient cells or cells which p8 mRNA levels have been selec-
tively knocked down are resistant to cannabinoid-induced
apoptosis; (4) p8 overexpression renders cannabinoid-resistant
tumor cells sensitive to THC; (5) THC administration upregulates
p8 in tumors in vivo; and (6) p8-deficient tumors are resistant to
the proapoptotic action of cannabinoids.
p8 belongs to the family of HMG-I/Y transcription factors and
was originally described as a gene induced during the acute
phase of pancreatitis (Mallo et al., 1997). Intriguingly, p8
seems to play a dual role in the control of cell fate. On the one
hand—and in line with the results presented here—p8 has
been implicated in a reduction of cell proliferation of pancreatic
(Malicet et al., 2003 and our unpublished observations) and
breast (Jiang et al., 2005a) tumor cells. On the other hand, ex-
pression of this protein is necessary for the establishment of
newly generated tumors (Vasseur et al., 2002a). In addition, p8
overexpression has been associated inversely to apoptosis in
samples obtained from biopsies of pancreatic (Su et al., 2001)
and breast cancer (Ito et al., 2005) but also directly to improved
prognosis of breast cancer (Jiang et al., 2005b). All these obser-
vations suggest that cell or tissue-specific factors may deter-
mine the final role played by p8 in the control of cell fate. In
line with this idea, by using the yeast two-hybrid system we
have recently identified several p8-interacting proteins including
c-Jun activation domain binding protein 1 (JAB1) and prothymo-
sin a (J.L.I. and C.M., unpublished data), both of which have
been implicated in the control of cell proliferation and apoptosis
(Emberley et al., 2005; Jiang et al., 2003). Thus, modulation of
the levels or the activity of these or other proteins in a particular
cellular or tumoral context could be one of the factors involved in
determining the final biological role of p8. In agreement with this305
A R T I C L EFigure 5. THC induces apoptosis via p8-depen-
dent ATF-4, CHOP, and TRB3 upregulation
A: Effect of p8 knockdown on THC-induced
ATF-4, CHOP, and TRB3 upregulation in U87MG
cells (n = 6; a representative RT-PCR experiment
is shown). Values of gene induction as deter-
mined by real-time quantitative PCR (expressed
as mean fold increase 6 SD relative to vehi-
cle-treated cells; n = 6; **p < 0.01 from vehicle-
treated cells; ##p < 0.01 from siRNAC THC-
treated cells) are shown in parentheses.
B: Effect of ISP-1 on ATF-4, CHOP, and TRB3 mRNA
levels of U87MG cells (n = 6; a representative
RT-PCR experiment is shown). Values of gene in-
duction as determined by real-time quantitative
PCR (expressed as fold increase 6 SD relative to
vehicle-treated cells; **p < 0.01 and *p < 0.05
from vehicle-treated cells; ##p < 0.01 and #p <
0.05 from THC-treated cells) are shown in paren-
theses.
C: Effect of C2-ceramide on ATF-4, CHOP, and
TRB3 mRNA levels of U87MG cells (n = 3; a repre-
sentative RT-PCR experiment is shown). Values
of gene induction as determined by real-time
quantitative PCR (expressed as fold increase rel-
ative to vehicle-treated cells in that experiment)
are shown in parentheses.
D: Effect of THC on p8, ATF-4, CHOP, and TRB3
mRNA levels of p8+/+and p8-deficient RasV12/
E1A-transformed MEFs (n = 3; a representative
RT-PCR is shown).
E and F: Effect of THC on the viability of U87MG
cells transfected with siRNAC, ATF-4-selective
(siATF-4), or TRB3-selective (siTRB3) siRNA (n = 6;
##p < 0.01 and #p < 0.05 from siRNAC THC-
treated cells). Upper panels: Analysis of ATF-4
(E) or TRB3 (F) mRNA levels in cells transfected
with siRNAC and siATF-4 (E) or with siRNAC and
siTRB3 (F). Representative RT-PCR experiments
are shown.
G: The panel shows a schematic of the proposed
mechanism of THC-induced apoptosis of tumor
cells. THC binds to CB receptors and stimulates
ceramide synthesis de novo via activation of ser-
ine pamitoyltransferase (SPT). Ceramide accu-
mulation leads to upregulation of p8 and in
turn of the ER stress-related genes ATF-4, CHOP,
and TRB3. Activation of this pathway induces ap-
optosis of tumor cells.
Data in E and F are expressed as mean 6 stan-
dard deviation. (Bars in E and F correspond to
standard deviation.)idea, stable overexpression of p8 sensitizes cannabinoid-resis-
tant tumor cells to a further proapoptotic stimulus but is not
enough to induce apoptosis by itself, suggesting that an alterna-
tive pathway that would be triggered by THC in cannabinoid-
resistant tumor cells may also be required—together with p8
upregulation—to produce a proapoptotic signal.
Although the molecular mechanisms whereby p8 mediates its
effects are not well established yet, it has been postulated that
this protein may act as a cotranscription factor to regulate
gene expression (Hoffmeister et al., 2002; Jiang et al., 2005a;
Garcia-Montero et al., 2001). In this report, analysis of gene ex-
pression profiles together with knockdown experiments has led
us to identify three genes—those encoding the transcription
factors ATF-4 and CHOP and the stress-related pseudokinase
TRB3—as p8-modulated genes in apoptosis. Of interest,
ATF-4 and CHOP have been shown to regulate the expression
of TRB3 in response to ER stress to induce apoptosis of human306tumor cells (Ohoka et al., 2005). A series of ER alterations such
as calcium depletion, protein misfolding, and impairment of pro-
tein trafficking to the Golgi triggers the ER stress response
(Schroder and Kaufman, 2005). When these ER alterations can-
not be repaired by this response, the damaged cells undergo
apoptosis. Several stimuli, including ischemia (Tajiri et al.,
2004), viral infection (Benali-Furet et al., 2005; Li et al., 2005),
and drugs such as tunicamycin (Ohoka et al., 2005) or cisplatin
(Mandic et al., 2003) induce apoptosis through this pathway,
which may play an important role in the control of tumor growth
(Ma and Hendershot, 2004). Detailed gene expression analysis
of THC-challenged glioma cells demonstrates that several pro-
teins related with the ER response (including caspase 12, Bip
[also designated as GRP-78], asparagine synthetase, and
Herp—in addition to the aforementioned CHOP, ATF-4, and
TRB3) are selectively upregulated in cannabinoid-sensitive
cells. In line with this observation, genetic downregulation ofCANCER CELL APRIL 2006
A R T I C L EFigure 6. THC and ER stress inducers act in a synergistic fashion on tumor
cells
A: Effect of THC on the viability of C6.4 cells infected with an empty or a p8-
overexpressing retroviral vector (n = 6; ##p < 0.01 and #p < 0.05 from cells
infected with the empty vector). Upper panel: analysis of p8 mRNA levels
in cells infected with empty and p8-overexpressing retroviral vector (a rep-
resentative RT-PCR experiment is shown).
B: Effect of THC on the viability of C6.4 cells infected with an EGFP (Ad-EGFP)
or a hemagglutinin-tagged-TRB3 (Ad-HA-TRB3)-overexpressing adenoviral
vector (n = 5; ##p < 0.01 and #p < 0.05 from Ad-EGFP-infected cells). Upper
panel: analysis of HA-TRB3 expression in Ad-EGFP and Ad-HA-TRB3-infected
cells (a representative Western blot experiment is shown).
C: Effect of thapsigargin on cell viability of p8+/+ and p8-deficient RasV12/
E1A-transformed MEFs (n = 4; **p < 0.01 and *p < 0.05 from vehicle-treated
cells; ##p < 0.01 and #p < 0.05 from the corresponding thapsigargin-treated
p8+/+ cells).
D: Effect of tunicamycin on cell viability of p8+/+ and p8-deficient RasV12/
E1A-transformed MEFs (n = 4; **p < 0.01 and *p < 0.05 from vehicle-treated
cells; ##p < 0.1 from the corresponding tunicamycin-treated p8+/+ cells).CANCER CELL APRIL 2006ATF-4 and TRB3 mRNA levels reduces THC-induced cell death,
and TRB3 overexpression sensitizes cannabinoid-resistant cells
to THC-induced apoptosis. Taken together, these findings
strongly support a major role for the ER stress response in the
proapoptotic action of cannabinoids on tumor cells.
Accumulation of de novo-synthesized ceramide has been im-
plicated in the proapoptotic action of cannabinoids in glioma
cells (Blazquez et al., 2004; Galve-Roperh et al., 2000; Gomez
del Pulgar et al., 2002a). Moreover, ceramide levels have been
inversely associated with malignant progression of human glial
tumors (Riboni et al., 2002). However, the molecular mechanism
whereby ceramide mediates these actions has remained elu-
sive. Our findings show that de novo-synthesized ceramide is in-
volved in the upregulation of p8 and its downstream targets, and
that p8 may be a component of the ceramide proapoptotic cas-
cade. Although accumulation of complex sphingolipids had
been implicated in activation of the ER stress pathway (Tessitore
et al., 2004), we did not observe major changes in the glyco-
sphingolipid profile of our cells upon cannabinoid treatment.
Moreover, inhibition of GCS—the enzyme that catalyzes the
rate-limiting step of glycosphingolipid biosynthesis—did not
change the response to cannabinoid treatment of tumor cells.
Taken together, these observations support a role for ceramide
rather than for glycosphingolipids in the proapoptotic effect of
THC.
In this report, we show that the proapoptotic effect of canna-
binoids on tumor cells is mediated by a ceramide-dependent
upregulation of the stress protein p8 and several downstream
targets (ATF-4, CHOP, and TRB3) related with the ER stress
proapoptotic pathway (Figure 5G). Moreover, we provide evi-
dence that p8 upregulation also takes place in vivo and that
resistance to cannabinoid treatment is associated with a de-
creased activation of the p8-regulated proapoptotic pathway.
Our results also support that cannabinoid treatment does not
activate this pathway in nontransformed cells, in line with the be-
lief that cannabinoid proapoptotic action is selective for tumor
versus nontumor cells (Guzman, 2003), and that cannabinoids
act in a synergic fashion with ER stress inducers as well as
with other antitumoral agents. Efficacious treatment of cancer
will require in the future the use of selective strategies, including
most likely the combination of several drugs and therapeutic
approaches. The identification of the p8-regulated pathway de-
scribed here may contribute to the design of therapeutic strate-
gies for inhibiting tumor growth. In particular, our findings can
help to improve the efficiency and selectivity of a potential can-
nabinoid-based antitumoral therapy.
Experimental procedures
Reagents
Z-DQMD-FMK (caspase 3 inhibitor), Z-VAD-FMK (pan-caspase inhibitor),
rotenone, N-(n-butyl)deoxynojirimycin (NDJ), and DL-Threo-1-phenyl-2-pal-
mitoylamino-3-morpholino-1-propanol (PPMP) were from Sigma Chemical
E–H: Effect of THC and thapsigargin (E), tunicamycin (F), doxorubicin (G), or
cisplatin (H; CDDP) on viability of U87MG cells (E, n = 4; F, n = 4; G, n = 4; H,
n = 4; **p < 0.01 from vehicle-treated cells; ##p < 0.01 from THC-treated cells;
UUp < 0.01 from the corresponding thapsigargin [E]-, tunicamycin [F]-, doxo-
rubicin [G]-, or cisplatin [H]-treated cells).
Data in A–H are expressed as mean6 standard deviation. (Bars correspond
to standard deviation.)307
A R T I C L EFigure 7. p8 mediates THC antitumoral action in
tumor xenografts
A: Effect of THC administration on the growth of
U87MG-cell tumor xenografts in nude mice (n =
8 for each condition; **p < 0.01 and *p < 0.05
from vehicle-treated tumors). B: Effect of THC ad-
ministration on apoptosis of U87MG-cell tumor
xenografts. Results correspond to three dis-
sected tumors for each condition and are ex-
pressed as the percentage of TUNEL-positive
cells relative to the total number of cells in
each section (**p < 0.01 from vehicle-treated tu-
mors; a representative photomicrograph is
shown). C: Immunohistochemical analysis of p8
expression in U87MG-cell tumor xenografts. Rep-
resentative photomicrographs of p8 immuno-
staining (dark brown) in sections of two tumors
treated with vehicle (left panels) or THC (right
panels) are shown.D: p8 and TRB3 mRNA expres-
sion (as determined by real-time quantitative
PCR) in U87MG-cell tumor xenografts. The plot
represents gene expression (in fold number) of
each individual tumor relative to one of the vehi-
cle-treated tumors. (n = 6 for each condition).
E and G: Effect of THC administration on the
growth of p8+/+ (E) or p8-deficient (G) RasV12/
E1A-transformed MEF-tumor xenografts in nude
mice (E, n = 3 for each condition; F, n = 6 for
each condition; **p < 0.01 and *p < 0.05 from
vehicle-treated tumors). F and H: Effect of THC
administration on apoptosis of p8+/+ (F) and p8-
deficient (H) RasV12/E1A-transformed MEF-tumor
xenografts. Results correspond to three dissected
tumors for each condition and are expressed as
the percentage of TUNEL-positive cells relative to
the total number of cells in each section (**p <
0.01 from vehicle-treated tumors; representative
photomicrographs are shown). Data in A, B, and
E–H are expressed as mean 6 standard devia-
tion. (Bars correspond to standard deviation.)Co (St. Louis, MO). Myriocin (ISP-1) was from Biomol (Plymouth Meeting,
PA). Radiochemicals were from Amersham Biosciences (Piscataway, NJ).
Cell culture and viability
Primary cultures of brain tumor cells were obtained from biopsies donated by
the Tumor Bank Network coordinated by the Spanish Cancer Research Cen-
tre. HG1 was carried by a 38-year-old man, and HG2 was carried by a 51-
year-old man; both were diagnosed by the Pathology Department of Hospital
Ramo´n y Cajal (Madrid, Spain). Tumor samples were homogenized, digested
with type Ia collagenase (Sigma) for 1 hr, and incubated on ice for 10 min. The
supernatant was collected and, after centrifugation to discard the remaining
death-floating cells, resuspended in DMEM containing 15% FBS. Finally,308cells were seeded at a density of 400,000 cells/cm2 and kept in culture for
2 weeks in DMEM containing 15% FBS and 1% glutamine. Cortical astro-
cytes were prepared from 24-hr-old Wistar rats as previously described (Go-
mez del Pulgar et al., 2002b; see also Supplemental Data). C6.9 and C6.4
cells were cultured as described (Galve-Roperh et al., 2000). U87MG,
Gos3, MiaPaCa2, A375, and p8+/+ and p8-deficient RasV12/E1A-transformed
MEFs were cultured in DMEM containing 10% FBS as described (Vasseur
et al., 2002a). Cells were transferred to a serum-free medium (except primary
cultures of brain tumor cells, A375 cells, and RasV12/E1A-transformed MEFs,
which were transferred to media containing 0.5%, 0.1%, and a 2% FBS, re-
spectively) 18 hr before the different treatments were performed. Cell viability
was determined with the CellTiter96 Aqueous One Solution Reagent (MTS)
(Promega, Madison, Wisconsin).CANCER CELL APRIL 2006
A R T I C L EFigure 8. THC administration upregulates p8 in
glioblastomas from patients
A: Effect of THC on the viability of primary tumor
cell cultures obtained from two human glioblas-
tomas (HG1, human glioblastoma 1; HG2, hu-
man glioblastoma 2).
B: Effect of THC administration on p8, ATF-4,
CHOP, and TRB3 mRNA levels of HG1 and HG2
cells as determined by real-time quantitative
PCR.
C: Immunohistochemical analysis of cleaved
caspase 3 in two patients with glioblastoma mul-
tiforme before and after THC treatment. Repre-
sentative photomicrographs are shown. Values
on the lower right corner of each panel express
the percentage of caspase 3-positive staining
in each sample.
D: Immunohistochemical analysis of p8 expres-
sion in two patients with glioblastoma multiforme
before and after THC treatment. Representative
photomicrographs are shown.Caspase 3/7 activity
Caspase 3/7 (DVEDase) activity was determined using a luminogenic sub-
strate (Caspase Glo, Promega).
Analysis of mitochondrial transmembrane potential
Cells (approximately 0.53 106 cells per assay) were trypsinized, collected by
centrifugation, washed once, and incubated for 30 min at room temperature
with 0.25 mM tetramethylrhodamine methyl ester (TMRM) (Molecular Probes,
Leiden, The Netherlands). After incubation for an additional minute with 1 mM
Hoechst 33258 (Molecular Probes), fluorescence intensity was analyzed us-
ing a LSR flow cytometer (Becton Dickinson, San Jose, CA). Ten thousand
cells were recorded in each analysis.
Western blot
Western blot analysis was performed as described (Gomez del Pulgar et al.,
2002b). Anti-p8 antibody (Abcam, Cambridge, UK), anti-HA monoclonal an-
tibody (Roche, Basel, Switzerland), and anti-Flag monoclonal antibody
(Sigma) were used.
Analysis of gene expression in C6.9 and C6.4 cells
Total RNA was isolated from control and THC-treated C6.9 and C6.4 cells,
amplified, labeled, and hybridized on a 22k rat array (Agilent Technologies)
(see MIAME in the Supplemental Data).
Analysis of gene expression in rat astrocytes
Total RNA was isolated from vehicle and THC-treated rat primary astrocytes,
amplified, labeled, and hybridized on a 22k rat array (Agilent Technologies)
(see MIAME in the Supplemental Data).
Analysis of gene expression in p8-deficient MEFs
MEFs from p8 knockout mice immortalized with rasV12/E1A were infected
with an empty or a p8-overexpressing retroviral vector as described (Vasseur
et al., 2002a). Total RNA was isolated, subsequently amplified, labeled, and
hybridized to the GeneChip Mouse Expression Array 430A (Affymetrix, Santa
Clara, California) (see MIAME in the Supplemental Data).CANCER CELL APRIL 2006Transfections
U87MG cells (75% confluent) were transfected with siRNA duplexes using
the X-tremeGENE siRNA Transfection Reagent (Roche) or with a Flag-Bcl-
xL-expressing plasmid using Lipofectamine 2000 (Invitrogen). Twenty-four
hours after transfection, cells were trypsinized and seeded at a density of
5000 cells/cm2. Cells were transferred to a serum-free medium 18 hr before
performing the different treatments. Transfection efficiency was >70% as
monitored by using a control fluorescent siRNA (Qiagen, Hilden, Germany)
or a GFP-expressing plasmid.
Infections with p8 retroviral vector
C6.4 cells (75% confluent) were infected with an empty or a p8-overexpress-
ing retroviral vector as described (Vasseur et al., 2002a). Control and
p8-overexpressing C6.4 cells were isolated by selection in puromycin
(4.5 mg/ml).
Infections with TRB3 adenoviral vector
C6.4 cells (75% confluent) were infected for 1 hr with supernatants obtained
from HEK293 cells transduced with adenoviral vectors carrying EGFP or
a hemagglutinin-tagged form of rat TRB3 (Iynedjian, 2005). Infection effi-
ciency was >80% as determined by EGFP fluorescence.
RNA interference
Double-stranded RNA duplexes corresponding to human p8 (50-GGAG
GACCCAGGACAGGAU-30), human ATF-4 (50-GCCUAGGUCUCUUAGAU
GA-30), human TRB3 (50-UCAUCUAAGAGAACCUAGGC-30), human GCS
(50-CCAGGAUAUGAAGUUGCAA-30), and a nontargeted control (50-UU
CUCCGAACGUGUCACGU-30) were purchased from Eurogentec (Liege,
Belgium).
Reverse transcription-PCR analysis
RNA was isolated with the RNeasy Protect kit (Qiagen). This procedure in-
cluded a subsequent DNase digestion step using the RNase-free DNase
kit (Qiagen). cDNA was obtained with Transcriptor (Roche). Primers were
used to amplify mRNA for human p8 (50-GAAGAGAGGCAGGGAAGACA-30
and 50-CTGCCGTGCGTGTCTATTTA-30 [571 bp product]), human TRB3
(50-GCCACTGCCTCCCGTCTTG-30 and 50-GCTGCCTTGCCCGAGTAT
GA-30 [538 bp product]), human ATF-4 (50-AGTCGGGTTTGGGGGCTG309
A R T I C L EAAG-30 and 50-TGGGGAAAGGGGAAGAGGTTGTAA-30 [436 bp product]),
human CHOP (50-GCGTCTAGAATGGCAGCTGAGTCATTGCC-30 and 50-G
CGTCTAGATCATGCTTGGTGCAGATTC-30 [508 bp product]), human GCS
(50-CCTTTCCTCTCCCCACCTTCCTCT-30 and 50-GGTTTCAGAAGAGAGA
CACCTGGG-30 [300 bp product]), mouse p8 (50-GAAGCTGCTGCCAATAC
CAACC-30 and 50-TAGCTCTGCCCGTCTACCCTC-30 [359 bp product]),
mouse ATF-4 (50-GAAACCTCATGGGTTCTCCA-30 and 50-AGAGCTCATCT
GGCATGGTT-30 [202 bp product]), mouse CHOP (50-GCAGCCATGGCA
GCTGAGTCCCTGCCTTCC-30 and 50-CAGACTCGAGGTGATGCCCACTGT
TCATGC-30 [536 bp product]), mouse TRB3 (50-GCTGGGCTCTCGGCTCC
TTTACAT-30 and 50-GAGGATTCCCAGGGCCACAAGTCG-30 [487 bp prod-
uct]) human/mouse GAPDH (50-GGGAAGCTCACTGGCATGGCCTTCC-30
and 50-CATGTGGGCCATGAGGTCCACCAC-30 [322 bp product]). PCR reac-
tions were performed using the following parameters: 95ºC for 5 min, 94ºC
for 30 s, 57ºC (p8, ATF-4, CHOP, GCS, mTRB3, and GAPDH) or 52ºC
(hTRB3) for 30 s, and 72ºC for 1 min, followed by a final extension step at
72ºC for 5 min. The number of cycles was adjusted to allow detection in
the linear range.
Real-time quantitative PCR
cDNA was obtained with Transcriptor (Roche). Taqman probes were ob-
tained from Applied Biosystems (Foster City, California). Amplifications
were run in a 7700 Real-Time PCR System (Applied Biosystems). Each value
was adjusted by using 18S RNA levels as reference.
Ceramide levels
Ceramide levels were determined as previously described (Gomez del Pulgar
et al., 2002a).
Metabolic labeling of complex sphingolipids
U87MG cells were incubated with [14C]serine (6 mCi/106 cells) for 24 hr in se-
rum-free medium before the different treatments were performed. After incu-
bation with either vehicle or THC for 24 additional hr in the same medium,
cells were harvested; lipids were extracted with chloroform/methanol and
subjected to phase partition with PBS/water. The upper phase was isolated,
and ganglioside content was analyzed by thin layer chromatography (TLC)
using chloroform/methanol/0.22% CaCl2 (55:45:10, by vol.). The lower phase
(containing all non-ganglioside lipids) was subjected to a mild alkaline meth-
anolysis procedure and separated by TLC using chloroform/methanol/
ammonia/water (70:30:2:2.5, by vol.).
In vivo treatments
Tumors were induced in nude mice by subcutaneous injection of 10 3 106
U87MG cells in PBS supplemented with 0.1% glucose or 10 3 106 p8+/+ or
p8-deficient RasV12/E1A-transformed MEFs in DMEM containing 10%
FBS. Tumors were left to grow until they reached an average volume of
200–250 mm3 (which for U87MG cells and transformed MEFs took around
2 weeks and 10 days, respectively, in the conditions used) and animals
were assigned randomly to the different groups. At this point, vehicle or
THC (15 mg/kg/day) in 100 ml of PBS supplemented with 5 mg/ml defatted
and dialyzed BSA was daily administered in a single peritumoral injection. Tu-
mors were measured with external caliper, and volume was calculated as
(4p/3) 3 (width/2)2 3 (length/2).
Human tumor samples
Tumor biopsies were obtained from two of the patients enrolled in an ongoing
phase I/II clinical trial at the Neurosurgery Department of Tenerife University
Hospital (Spain) aimed at investigating the effect of THC administration on
the growth of recurrent glioblastoma multiforme. The patients had failed
standard therapy, which included surgery, radiotherapy (60 Gy), and temozo-
lamide chemotherapy (2 cycles); had clear evidence of tumor progression on
sequential magnetic resonance scanning before enrollment in the study; had
received no anticancer therapy forw6 months; and had a fair health status
(Karnofski performance score = 90). The patients provided written informed
consent. The protocol was approved by the Clinical Trials Committee of Te-
nerife University Hospital and by the Spanish Ministry of Health.
The recurrent tumors (Figure S5) were extensively removed by surgery, bi-
opsies were taken, and the tip (w5 cm) of a silastic infusion catheter (9.6
French; 3.2 mm diameter) was placed into the resection cavity. The infusion
catheter was connected to a Nuport subclavicular subcutaneous reservoir.310Each day, 0.5–1.5 (median 1.0) mg THC (100 mg/ml in ethanol solution) was
dissolved in 30 ml physiological saline solution supplemented with 0.5%
(w/v) human serum albumin, and the resulting solution was filtered and ad-
ministered at a rate of 0.3 ml/min with a syringe pump connected to the sub-
cutaneous reservoir. Patient 1 started the treatment 4 days after the surgery
and received THC for 19 days. The posttreatment biopsy was taken 19 days
after the cessation of THC administration. Patient 2 started the treatment
4 days after the surgery and received THC for 16 days. The posttreatment bi-
opsy was taken 43 days after the cessation of THC administration. Samples
were fixed in formalin and embedded in paraffin.
Immunohistochemistry and TUNEL
Samples from tumor xenografts were dissected and frozen. Samples from
human tumors were fixed in 10% buffered formalin and then paraffin embed-
ded. After deparaffinization (only for human tumor samples) and blocking of
nonspecific binding, sections were incubated with an anti-human active-
caspase 3 antibody (1:200; Promega, Madison, Wisconsin) or with an anti-
human p8 antibody (1:500; Vasseur et al., 1999). Immunoperoxidase pro-
cedure was performed on xenograft samples using a Vectastain goat
anti-rabbit kit (Vector Laboratories, Burlingame, California) and on human tis-
sue using the Ventana gene II device with Ventana kits (Ventana, Strasbourg,
France). For TUNEL, samples were labeled with in situ cell death detection kit
(Roche). Caspase 3 labeling surface was quantified by an Olympus BX61 au-
tomated microscope (103 objective) using Samba 2050 image analyzer
(Samba Technologies, Meylan, France).
Statistics
Results shown represent means6 SD. Statistical analysis was performed by
ANOVA with a post hoc analysis by the Student-Neuman-Keuls test.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures and
five supplemental figures and can be found with this article online at http://
www.cancercell.org/cgi/content/full/9/4/301/DC1/.
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